Duality Advisers LP bought a new position in shares of Nektar Therapeutics (NASDAQ:NKTR) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund bought 124,626 shares of the biopharmaceutical company’s stock, valued at approximately $2,886,000. Duality Advisers LP owned about 0.07% of Nektar Therapeutics at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Canada Pension Plan Investment Board bought a new position in shares of Nektar Therapeutics during the first quarter worth approximately $44,000. Aigen Investment Management LP acquired a new position in Nektar Therapeutics in the 1st quarter valued at $64,000. NewSquare Capital LLC bought a new position in Nektar Therapeutics during the 1st quarter worth $71,000. Dupont Capital Management Corp acquired a new stake in shares of Nektar Therapeutics during the first quarter worth $80,000. Finally, Mercer Capital Advisers Inc. bought a new stake in shares of Nektar Therapeutics in the first quarter valued at about $89,000. Institutional investors and hedge funds own 98.13% of the company’s stock.

Shares of NKTR opened at $22.16 on Friday. The company has a quick ratio of 3.75, a current ratio of 3.79 and a debt-to-equity ratio of 0.11. The stock has a market cap of $4.14 billion, a PE ratio of -8.49 and a beta of 2.01. Nektar Therapeutics has a 12-month low of $13.63 and a 12-month high of $31.39. The business has a 50-day simple moving average of $23.05 and a two-hundred day simple moving average of $21.18.

Nektar Therapeutics (NASDAQ:NKTR) last released its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported ($0.53) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.77) by $0.24. Nektar Therapeutics had a negative return on equity of 28.83% and a negative net margin of 335.50%. The company had revenue of $50.57 million for the quarter, compared to analysts’ expectations of $46.88 million. During the same period in the previous year, the business posted ($0.68) earnings per share. The business’s quarterly revenue was up 79.2% compared to the same quarter last year. On average, equities research analysts expect that Nektar Therapeutics will post -2.55 EPS for the current year.

NKTR has been the subject of several analyst reports. SVB Leerink lifted their price objective on shares of Nektar Therapeutics from $17.00 to $18.00 and gave the stock a “market perform” rating in a research note on Friday, May 8th. BidaskClub downgraded shares of Nektar Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, July 14th. Benchmark initiated coverage on Nektar Therapeutics in a research report on Wednesday, April 22nd. They set a “buy” rating and a $26.00 price target on the stock. Cfra lowered Nektar Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, June 10th. Finally, Mizuho started coverage on Nektar Therapeutics in a research report on Tuesday, May 26th. They set a “buy” rating and a $35.00 target price for the company. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating and eleven have assigned a buy rating to the stock. Nektar Therapeutics has an average rating of “Hold” and an average price target of $31.39.

In related news, Director R Scott Greer sold 15,009 shares of the business’s stock in a transaction on Thursday, July 9th. The shares were sold at an average price of $25.00, for a total value of $375,225.00. Following the sale, the director now owns 284,973 shares of the company’s stock, valued at $7,124,325. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 2.99% of the stock is currently owned by company insiders.

Nektar Therapeutics Company Profile

Nektar Therapeutics, a biopharmaceutical company, develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States. The company develops NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; and NKTR-214, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in Phase I to treat immuno-oncology.

Featured Article: How can investors benefit from after-hours trading?

Want to see what other hedge funds are holding NKTR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Nektar Therapeutics (NASDAQ:NKTR).

Institutional Ownership by Quarter for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.